Regulatory T cells predict SABR outcomes in oligorecurrent NSCLC

  • Liu C & al.
  • Int J Radiat Oncol Biol Phys
  • 19 Aug 2019

  • curated by Craig Hicks
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Regulatory T-cell (Treg) level is an independent predictor of OS and PFS with stereotactic ablative radiotherapy (SABR) for pulmonary recurrence-based oligometastatic NSCLC.

Why this matters

  • Patients with high pretreatment Treg levels may need other treatments in addition to SABR.

Study design

  • Prospective study of 63 patients with pulmonary recurrence-based oligometastatic NSCLC receiving SABR (66.7% men; median age, 63 [range, 44-84] years).
  • Median follow-up was 19.1 months.
  • Funding: National Key Research and Development Program of China; Shandong Key Research and Development Program; National Natural Science Foundation of China.

Key results

  • Estimated OS rates at 1, 2, and 3 years were 84.3%, 63.4%, and 44.0%, respectively. 
    • Corresponding PFS rates were 55.2%, 30.9%, and 25.7%.
  • Patients with high Treg levels had poorer OS (16.1 months vs not reached; P=.006) and PFS (11.0 vs 21.7 months; P=.013).
  • Multivariate analyses confirmed Treg level as an independent predictor of both OS (HR, 2.68; P=.038) and PFS (HR, 2.35; P=.011).

Limitations

  • Small sample size.
  • Tumor histology varied across patients.
  • Potential misclassification of second primary cancer as recurrent disease.